Baseline demographic and clinical characteristics of the patients. Data are number (%) or mean (SD) unless otherwise indicated.
| Characteristic | Adalimumab, n = 43 | Infliximab, n = 48 |
|---|---|---|
| Sex, F:M | 5.1:1 | 2.7:1 |
| Age, yrs | 8.8 (4.4) | 10.5 (4.3) |
| Age at arthritis onset, yrs | 3.9 (3.2) | 4.8 (3.2) |
| Range | 1.0–15.6 | 0.6–13.4 |
| Age at uveitis onset, yrs | 4.7 (4.2) | 4.9 (3.3) |
| Range | 1.0–18.0 | 0.9–15.0 |
| Time interval arthritis/uveitis, mo | 18.5 (24.9) | 27.2 (33.1) |
| Range | 0.0–120.1 | 0.0–137.7 |
| Uveitis duration, yrs | 4.1 (3.5) | 5.5 (4.7) |
| Range | 0.0–15.9 | 0.3–18.0 |
| Previous treatments | ||
| Methotrexate | 35* (81.4) | 41 (85.4) |
| Cyclosporine A | 3 (7.0) | 10 (20.8) |
| Corticosteroid dependency | 17 (39.5) | 18 (37.5) |
↵* Five patients in this group were intolerant to methotrexate and were not considered because of the very short (< 3 weeks) treatment duration.